

Regarding Item 5 (Elections to the Supervisory Board)



Dr. Michael Majerus

Dr. Michael Majerus is not a member of any other statutory supervisory boards.

Dr. Michael Majerus is not a member of any comparable domestic and foreign controlling bodies of business enterprises.

Curriculum vitae of the proposed candidate Dr. Michael Majerus

Dr. Michael Majerus, born 1961 in Cologne, studied business administration at the University of Cologne, graduating with a degree in business administration. After completing his doctorate in economics at the University of Siegen, he began his professional career in controlling at Mannesmann AG in 1989. In the following years, he held various management positions in Mannesmann Group's finance department. From 1999 to 2000, he was responsible for controlling and accounting at Mannesmann Group as the central divisional head and, following the takeover by Vodafone, worked in the same function for the industrial companies grouped under ATECS Mannesmann AG.

From the end of 2000 to 2006, he was a member of the Management Board and CFO of the Memory Products Division of Infineon Technologies AG. When the division became legally independent as Qimonda AG in 2006, he was appointed as the company's CFO and investor relations director, and implemented the company's IPO in New York. After leaving Qimonda AG, he was a member of the Management Board (CFO) of PHOENIX Pharmahandel GmbH & Co KG from 2009 to 2013.

In July 2014, he assumed the role of Chief Financial Officer of SGL Carbon SE, a post which he held up to and including November 2020. In addition, he led the company as CEO from September 2019 to May 2020. Dr. Majerus is a shareholder of Neofon GmbH and has held various mandates on the supervisory board or comparable bodies of companies in several European countries as well as in the USA, China and Taiwan over the past twenty years.

Dr. Majerus has been a member of the BRAIN Supervisory Board since 7 March 2019 and is currently chair of the Audit Committee.

In addition to the above information, with regard to C.13 of the German Corporate Governance Code, it is stated that, in the Supervisory Board's opinion, Dr. Majerus has no other personal or business relations with the Company or its Group companies, the corporate bodies of the Company or a shareholder with a significant interest in the Company that would require disclosure under C.13 of the German Corporate Governance Code. In the Supervisory Board's opinion, Dr. Majerus is to be regarded as independent in the meaning of the German Corporate Governance Code. Moreover, the Supervisory Board has assured itself of the proposed candidates' ability to devote the expected amount of time in each case.